GARP Research Maintains a 'Buy' on Edwards Lifesciences (EW); Hospiteal Interest in TAVI Remains High
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $87.75 +0.91%
Rating Summary:
23 Buy, 18 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
23 Buy, 18 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
GARP Research maintains a 'Buy' on Edwards Lifesciences (NYSE: EW).
Analyst, Alastair Mackay, said, "Edwards controls half of the growing market in its core business (heart valves), and new minimally-invasive technologies offer the potential to accelerate revenue growth and expand profitability over the next few years. Edwards prices a SAPIEN valve and delivery system at about five times as much as a surgically-implanted valve. Still, minimally-invasive delivery slightly lowers the overall cost of a valve-replacement procedure to the hospital and the third-party payer. In the U.S., Edwards should have the transcatheter-valve market to itself until at least 2014, the earliest possible date for approval of Medtronic’s (NYSE: MDT) competing CoreValve ReValving System."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $82.69 yesterday.
Analyst, Alastair Mackay, said, "Edwards controls half of the growing market in its core business (heart valves), and new minimally-invasive technologies offer the potential to accelerate revenue growth and expand profitability over the next few years. Edwards prices a SAPIEN valve and delivery system at about five times as much as a surgically-implanted valve. Still, minimally-invasive delivery slightly lowers the overall cost of a valve-replacement procedure to the hospital and the third-party payer. In the U.S., Edwards should have the transcatheter-valve market to itself until at least 2014, the earliest possible date for approval of Medtronic’s (NYSE: MDT) competing CoreValve ReValving System."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $82.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW)
- Costco Wholesale (COST) PT Raised to $710 at Citi
- Novartis (NVS) PT Raised to $108 at CFRA
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
